As of 14 July 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC). The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 14 July to 28 July (Tuesday) 2026.

As a preliminary recommendation, the HTA Council recommends the government financing of abiraterone acetate 500mg film-coated tablet. However, due to the substantial budget impact of financing this drug, the DOH should explore conducting price-lowering strategies to ensure affordability and sustainable access to this treatment.

For the supporting evidence reviewed and discussed by the HTA Council, please refer to the document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 28 July 2026 (Tuesday), for the consideration of the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format and those submitted beyond the deadline shall not be entertained.